Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Total Non-Current Liabilities (2016 - 2020)

Niagen Bioscience (NAGE) has disclosed Total Non-Current Liabilities for 8 consecutive years, with $20.2 million as the latest value for Q2 2020.

  • On a quarterly basis, Total Non-Current Liabilities fell 30.73% to $20.2 million in Q2 2020 year-over-year; TTM through Jun 2020 was $20.2 million, a 30.73% decrease, with the full-year FY2019 number at $19.6 million, up 32.84% from a year prior.
  • Total Non-Current Liabilities was $20.2 million for Q2 2020 at Niagen Bioscience, up from $18.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $29.1 million in Q2 2019 to a low of $6.6 million in Q4 2016.
  • A 5-year average of $14.0 million and a median of $13.2 million in 2016 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: surged 153.45% in 2019, then crashed 30.73% in 2020.
  • Niagen Bioscience's Total Non-Current Liabilities stood at $9.4 million in 2016, then decreased by 8.66% to $8.6 million in 2017, then soared by 72.33% to $14.8 million in 2018, then surged by 32.84% to $19.6 million in 2019, then increased by 2.69% to $20.2 million in 2020.
  • Per Business Quant, the three most recent readings for NAGE's Total Non-Current Liabilities are $20.2 million (Q2 2020), $18.8 million (Q1 2020), and $19.6 million (Q4 2019).